Categories AlphaGraphs, Earnings, Industrials
Infographic: Lockheed Martin (LMT) Q2 2022 earnings, revenue decline
Aerospace company Lockheed Martin Corporation (NYSE: LMT) Tuesday said its sales decreased 9% in the second quarter of 2022, resulting in a marked drop in net profit. The results also missed the consensus estimates.
Reflecting the impact of pandemic-related business disruption and macroeconomic headwinds, Lockheed Martin’s net sales dropped 9% from last year to $15.4 billion in the June quarter. The number also came in below the consensus estimate.
Consequently, net income dropped to $309 billion or $1.16 per share from $1.8 billion or $6.52 per share in the second quarter of 2021. Adjusted profit, excluding special items, was $6.32 per share, compared to $6.42 per share last year. The bottom line fell short of expectations.
Check this space to read management/analysts’ comments on Lockheed Martin’s Q2 2022 results
Lockheed Martin’s shares declined early Tuesday following the earnings announcement, after closing the previous session lower.
Prior Performance
Looking for more insights on the earnings results? Click here to access the full transcripts of the latest earnings conference calls!
Most Popular
WMT Earnings: All you need to know about Walmart’s Q2 2023 earnings results
Walmart Inc. (NYSE: WMT) reported second quarter 2023 earnings results today. Total revenue increased 8.4% year-over-year to $152.9 billion. Revenues grew 9.1% in constant currency. Consolidated net income attributable to
Rivian (RIVN) reaffirms production goals. Will it be a smooth ride?
The evolution of the electric vehicle industry accelerated in recent years even as innovations in battery technology and affordability brought EVs into the mainstream. Encouraged by the success of market
Pfizer (PFE): A look at the headwinds and tailwinds this pharma giant faces in the near term
Shares of Pfizer Inc. (NYSE: PFE) were down on Monday. The stock has dropped 15% year-to-date and there is a mixed sentiment surrounding the company’s growth prospects. Pfizer has benefited
